FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES

• Main Authors: SELBY, Matthew Duncan, ZHU, Zhaoning, KEYAERTS, Jean, SHAW, Michael Alan, SWINNEN, Dominique Louis Léon, QUINCEY, Joanna Rachel, HUTCHINGS, Martin Clive, DELIGNY, Michael, EVRARD, Yves, JOHNSON, James Andrew, FORICHER, Yann, DE HARO GARCIA, Teresa, SCHIO, Laurent, FILOCHE-ROMME, Bruno, BROOKINGS, Daniel Christopher, MAC COSS, Malcolm, CALMIANO, Mark Daniel, JADOT, Sophie, XUAN, Mengyang, HEER, Jag Paul
• Format: Patent
• Language: English; French; German
• Published: 28.07.2021
• Subjects: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM; CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.